Overview

* Humacyte ( HUMA ) Q3 net income beats analyst expectations, despite a slight miss in operating income

* Company's Q3 revenue increased significantly due to Symvess sales

Outlook

* Humacyte ( HUMA ) plans supplemental BLA filing for ATEV dialysis indication in second half of 2026

* Company aims to start first-in-human CTEV study for CABG in 2026

* Humacyte ( HUMA ) expands intellectual property with new patent for bioengineered esophagus

Result Drivers

* SYMVESS SALES GROWTH - Significant increase in Symvess sales driven by hospital approvals and inclusion in U.S. Defense Logistics Agency's ECAT

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net Beat -$17.51 -$25.13

Income mln mln (6

Analysts

)

Q3 Slight -$24.39 -$24.27

Operatin Miss* mln mln (6

g Income Analysts

)

Q3 Basic -$0.11

EPS

Q3 $25.14

Operatin mln

g

Expenses

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Humacyte Inc ( HUMA ) is $3.50, about 63.4% above its November 11 closing price of $1.28

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)